Background {#Sec1}
==========

High prevalence of gastrointestinal disorders among Asian population has caused significant suffering and it is generally considered by the health care professionals to be a leading cause for the incidence of a number of other concomitant disease conditions. Evidence based medicine has not yet succeeded in introducing any sufficiently safe and efficacious drug for the cure of gastrointestinal ailments. Most of the available remedies provide only short-term relief accompanied by various undesirable effects. Nevertheless, conventional phytotherapies have proved to be more cost-effective and long-lasting in the treatment of gastric problems \[[@CR1]\]. These herbal products have emerged as a remarkable source to contribute to the discovery of a number of lead compounds and contemporary marketed medicines. Around 61% of the total drugs launched globally have been extracted from naturally originated herbal products \[[@CR2]\].

In-vivo evaluation of crude plant extracts aids to screen out newer bioactive lead molecules and their further processing for structural exploration can lead to the development of novel therapies. For obtaining desirable therapeutic effects, pure form of bioactive constituents can be formulated into appropriate dosage forms as well as doses and dosing frequency can be decided \[[@CR3]\]. Many chronic disorders have been successfully cured by phytotherapies particularly by edible fruits being consumed as functional foods as well as their active constituents. Several previous studies have demonstrated the potential of crude extracts of a number of edible fruits to treat the gastrointestinal tract diseases \[[@CR4]\].

*Ficus palmata* commonly known as 'Fig' and locally "Injeer" belongs to the family Moraceae that consists of about 800 species \[[@CR5]\]. It is found in the Himalayan region, so also named as Wild Himalayan Fig and is mainly the native of Northern areas of Pakistan. Majority of the members of the family are very tall trees, shrubs and sporadically herbs often with milky juice \[[@CR6]\]. Variety of *Ficus* species are used in folk medicine as anti-inflammatory, anti-tumor and tonic medicament \[[@CR7]\]. Diseases such as epilepsy, jaundice, influenza, whooping cough, tonsillitis, bronchitis, enteritis, bacillary dysentery, toothache and bruises are also reported to be cured by *Ficus* extracts. Antioxidant activity was exhibited by *Ficus palmata* \[[@CR8]\]. Various pharmacological activities such as nephroprotective, hepatoprotective and anticoagulant activities are also possessed by this plant \[[@CR9]\].

The chemical analysis on genus *Ficus*, reveals the presence of sterols, terpenes, isoflavones, lignans, glycosides \[[@CR10]\], coumarins, furanocoumarin and chromone \[[@CR11]\]. Phytochemical investigation of the aerial parts of *Ficus palmata* resulted in the isolation of 6 compounds; germanicol acetate, psoralene, bergapten, vanillic acid, psoralenoside and flavone glycoside rutin \[[@CR10]\].

In the present study, we report anti-diarrheal, anti-secretary, anti-spasmodic, anti-motility and anti-ulcer effects. Aforementioned ethnomedicinal uses of the plant were validated by using baseline data from traditional uses and previous studies. Molecular docking of its constituents with known structure is done to find out the potential lead molecule responsible for pharmacological effects.

Methods {#Sec2}
=======

Plant material and extraction {#Sec3}
-----------------------------

Superior quality of *Ficus palmata* fruit weighing 2 kg were purchased from local market in Feb 2017. Plant was authenticated by a taxonmist Dr. Mushtaq Ahmad, at Department of Plant Sciences, Quaid-i-Azam University, Islamabad. Voucher specimen no. (ISL-B-24) was collected after submitting sample of specimen of these species to the herbarium at same department. The fruit (2 kg) was air-dried, crushed into powdered form and extracted at room temperature with aqueous-methanol (70:30) three times to obtain *Ficus plmata* crude extract (Fp.Cr).

Chemicals {#Sec4}
---------

Atropine sulphate, omeprazole, verapamil, loperamide, acetylcholine, charcoal, methanol and ethanol (Sigma Chemicals Co, St Louis, MO, USA) were used. Castor oil was obtained from KCL Pharma, Karachi, Pakistan.

Animals {#Sec5}
-------

Sprague-Dawley rats (180--220 g), Balb/C mice (25--30 g) and rabbits (1.0--1.2 kg), of either sex were obtained from animal house of the Riphah Institute of Pharmaceutical Sciences (RIPS) Islamabad. The animals were kept in 595 × 380 × 200 mm plastic cages at standard temperature (23--25 °C) and a 12:12 light:dark cycle with lights on at 08:00 and off at 20:00. They were fed with standard animal feed and tap water ad libitum. Animals were fasted before each experiment for 24 h. During housing, animals were monitored twice daily for health status. No adverse events were observed. All the animal experimental protocols were approved by Research and Ethics Committee of RIPS (Ref. no. REC/RIPS/2017/008) which were performed in accordance with the guidelines of "Principles of Laboratory Animal care" \[[@CR12]\]. All sections of this report adhere to the Animal Research:Reported of In-vivo Experiments (ARRIVE) Guidelines for reporting animal research. A completed ARRIVE guidelines checklist is included in Checklist S1.

Castor oil-induced diarrhea {#Sec6}
---------------------------

This method was previously reported by Umer et al. \[[@CR13]\]. All the test animals were fasted for 24 h prior to commencement of experimentation and were divided in five groups (*n* = 5). The floor of cage was lined with blotting paper in which animals were placed. First group was assigned as negative control group and received normal saline (10 mL/kg) orally, while second group was given with a dose of loperamide hydrochloride (10 mg/kg, p.o.), assigned as positive control. Third, fourth and fifth groups received 50, 100 and 300 mg/kg body weight of the extract orally respectively. After one hour of administration of the respective doses and treatments, all animals received castor oil (10 mL/kg, p.o.). Post treatment evaluation was carried out after waiting 4 h in order to analyze the diarrheal droppings presence, absence of diarrheal droppings was documented as a positive result.

Assessment of intestinal fluid accumulation {#Sec7}
-------------------------------------------

This method was previously described by Teke et al. \[[@CR14]\]. To study the intestinal fluid accumulation, enteropooling assay was used. Overnight fasted mice were taken and put into five assigned cages with five mice in each. Group I and II were administered with normal saline (10 mL/kg) and castor oil (10 mL/kg, p.o.) respectively. Extract doses of 50, 100 and 300 mg/kg intraperitoneally were given to Group III, IV and V respectively.

Standard drug atropine at dose 10 mg/kg was given to last group, 1 h prior induction with castor oil (10 mL/kg, p.o.). Mice were sacrificed by cervical dislocation after 30 min, then intestine was removed and weighed. The results were calculated as: (Pi/Pm) × 1000 where Pi is the weight (g) of the intestine and Pm is the weight of the animal. Later the dead animals were disposed off by burial method.

Isolated tissue preparation {#Sec8}
---------------------------

Before experiment rabbits were fasted for 24 h. Jejunal portion was isolated after cervical dislocation of rabbit and washed with Tyrode's solution. In tissue organ bath containing Tyrode's solution 2 cm of jejunal segment was suspended. Temperature of bath was kept at (37 °C) and proper aeration of 95% O~2~ and 5% CO~2~ (carbogen) is ensured. 1 g initial load was applied to tissue and allowed to equilibrate for 30 min before the addition of any drug. Following equilibration period, each preparation was then stabilized with sub-maximal concentration of ACh (0.3 μM) at 3 min interval until constant responses were recorded via a force displacement transducer (model FT-03) coupled with bridge 7 amplifier and power Lab 4/25 data acquisition system connected to computer running Lab-Chart 6 software (AD Instrument, Sydney Australia). The % change in the voluntary contractions of jejunum were recorded for Fp.Cr (0.01--3 mg/mL) \[[@CR15]\]. Later the dead animals were disposed off by burial method.

Ethanol-HCl induced ulcer assay {#Sec9}
-------------------------------

Rats weighing 250--280 g of either sex were distributed in 5 groups (*n* = 5). Group 1 served as a negative control received normal saline 10 mL/kg body weight, group 2 received 20 mg/kg, (p.o.) omeprazole as standard drug, group 3, 4 and 5 received 50, 100 and 300 mg/kg, (p.o.) of Fp.Cr respectively. All the animals were treated with 1 mL/100 g of ethanol-HCl mixture (p.o.) i.e. (0.3 M Hydrochloric acid and ethanol 60%) after 1 h to induce gastric ulcer. Animals were sacrificed via cervical dislocation one hour after administration of ethanol-HCl mixture. The stomach were removed and lesion index was estimated by measuring each lesion in mm along its greater curvature. Each lesion surface area was measured and scoring was done as described previously by \[[@CR16]\]. For each stomach lesion, ulcer index was taken as mean ulcer score (US). For each stomach injury sum of the lengths (mm) of all sores was utilized as the ulcer index (UI). The gastro protective assessment was displayed as an inhibition percentage (I %) calculated by the following formula:

I (%) = (USc -- USt) 100/USc.

Where USc = ulcer surface area of control and USt = ulcer surface area of test drug group.

Later the dead animals were disposed off by burial method.

Charcoal meal transit time {#Sec10}
--------------------------

Gastrointestinal transit time was estimated utilizing the charcoal meal test \[[@CR17]\]. Rats were fasted for 24 h, the test groups received the extract at 50, 100 and 300 mg/kg body weight doses, where as positive control group received atropine sulfate (0.1 mg/kg, i.p.), while the negative control group received normal saline (10 mL/kg, p.o.). 30 mins after all treatments, all the animals were sacrificed by cervical dislocation. The small intestine was excised after which the distance travelled by charcoal meal through the organ was expressed as a percentage of the length of the small intestine according to the following expression.

Intestinal transit (%) = (Distance moved by charcoal meal/ total length of intestine) (cm) × 100.

Later the dead animals were disposed off by burial method.

Computational studies {#Sec11}
---------------------

3-D structures of the test compounds bergapten, psoralene, psoralenosid and germanicol acetate were constructed by using the software of Gauss View 5.0. 3 dimensional structures of reference drugs were prepared through Discovery Studio Visualizer (2016) as shown in Fig. [1](#Fig1){ref-type="fig"}. Through same software, polar hydrogen atoms (H-atoms) were added in it and then saved as PDB file. Reference drugs included phenoxy benzamine, verapamil, calmozoilum, domperidone, ranitidine, piranzapine, atropine, loperamide, omeprazole and pyrilimiine. 3-D structures of selected targets possibly involved in the gut physiology, were retrieved from the website of RCSB protein data bank as represented in Fig. [2](#Fig2){ref-type="fig"}. Selected targets included adrenergic α~1~ receptor (PDB ID: 3538), muscranic M~1~ (PDB ID: 5CXV), muscranic M~3~ (PDB 9 ID: 4 U14), dopaminergic D~2~ (PDB ID: 6CM4), calmodulin (PDB ID: 1CTR), mu-opioid (PDB ID: 5CM), voltage gated L-Type calcium channel (PDB ID: 1T3S), histaminergic H~1~ (PDB ID: 3RZE), histaminergic H~2~ (PDB ID: P25021) and H^+^/K^+^ ATPase (PDB ID: 5YLU). Water molecules and ligands were removed along with addition of polar H-atoms by using same software and then saved in PDB format. Autodock Vina which is a geometry based automatic docking tool is used through which molecular docking was performed. A definite value of Root Mean Square of deviation clustering 2 was taken as criteria for elimination of irrelevant findings. Evaluation of docking result was based on atomic energy in Kcal/mol \[[@CR18]\]. Assessment of top twenty conformations was performed and only one pose having lowest value of atomic energy in Kcal/mol was further processed for post dock analysis through Discovery Studio Visulizer 2016. Assessment in 2-D design was made to check the most extreme restricting interactions of complex framed amongst amino acid residues and ligands including: valine (VAL), alanine (ALA), proline (PRO), arginine (ARG), threonine (THR), lysine (LYS), proline (PRO), glycine (GLY), glutamine (GLN), asparagine (ASN), cysteine (CYS), methionine (MET), glutamic acid (GLU), histidine (HIS), phenylalanine (PHE), isoleucine (ILE), tyrosine (TYR), serine (SER), threonine (THR), aspartic acid (ASP) and tryptophan (TRP). Fig. 13D-structures of reference drugs: **a** phenoxy benzamine, **b** verapamil, **c** calmozolium, **d** domperidone, **e** ranitidine, **f** piranzapine, **g** atropine, **h** loperamide, **i** omeprazole and (**j**) pyrilimine, drawn through Chem Sketch 2015, 2.5 and saved in PDB format through Biovia Discovery Studio 2016. Atoms are shown by colors; gray color (carbon atoms), white color (hydrogen atoms), red color (oxygen atoms), blue color (nitrogen atoms), dark red (bromine), and yellow color (sulfur atoms) Fig. 23D-structures of protein targets: **a** adrenergic α~1~ receptor, **b** muscranic M~1~, **c** muscranic M~3~, **d** dopaminergic D~2~, **e** calmodulin, **f** mu-opioid, **g** voltage gated L-Type calcium channel, **h** histaminergic H~1~, **i** histaminergic H~2~, and **(j)** H^+^/K^+^ ATPase pump

Statistical analysis {#Sec12}
--------------------

Data was expressed as Mean ± SEM (*n* = 5) and median effective concentrations (EC50) having 95% confidence intervals. Statistical analysis of the results was analyzed using one-way ANOVA followed by *post-hoc* Tukey's test. Chi square test was used in the case of the antidiarrheal data, where *p* \< 0.05 was regarded as significant. Non-linear regression using Graph 10 Pad program (GraphPAD, SanDiego, CA-USA) was used to analyze the concentration-response curves.

Result {#Sec13}
======

Effect on castor-oil induced diarrhea {#Sec14}
-------------------------------------

Fp.Cr showed a dose-dependent (50--300 mg/kg) protective effect. The saline treated group (negative control) did not show any protection against castor oil-induced diarrhea. Fp.Cr, exhibited 20, 60 and 80% protection from diarrhea at 50, 100 and 300 mg/kg (*p* \< 0.05 vs. saline group). Positive control group, loperamide (10 mg/kg) showed 100% protection (*p* \< 0.01 vs. saline group) (Table [1](#Tab1){ref-type="table"}). Table 1Effect of the *Ficus palmata* crude extract (Fp.Cr) and loperamide against castor oil induced diarrhea in miceTreatment\
(mg/kg)No of mice (out of 5) with diarrheaProtection\
(%)Saline (10 mL/kg) + castor oil50Fp.Cr (50 mg/kg) + castor oil420Fp.Cr (100 mg/kg) + castor oil2^\*^60Fp.Cr (300 mg/kg) + castor oil1^\*^80Loperamide (10 mg/kg) + castor oil0^\*\*^100^\*^*p* \< 0.05, ^\*\*^*p \<* 0.01 compared to saline group, data analyzed by Chi-squared test

Effect on intestinal fluid accumulation {#Sec15}
---------------------------------------

When tested against castor oil-induced intestinal fluid accumulation in mice, Fp.Cr exhibited a dose-dependent (50--300 mg/kg) anti-secretory effect. In the saline treated group intestinal fluid accumulation was 81.9 ± 0.84 (mean ± SEM, *n* = 5), castor oil-treated group showed 122.5 ± 0.55 (*p* \< 0.001 vs. saline group). Fp.Cr at the doses of 50, 100 and 300 mg/kg reduced the castor oil-induced fluid accumulation to 100.30 ± 0.47 (*p* \< 0.001 vs. castor oil group), 89.32 ± 0.86 (*p* \< 0.001 vs. castor oil group) and 80.98 ± 0.67 (*p* \< 0.001 vs. castor oil group) respectively. Atropine at the dose of 10 mg/kg decreased the intestinal fluid accumulation to 74.34 ± 0.69 (*P* \< 0.001 vs. castor oil group) as shown in Fig. [3](#Fig3){ref-type="fig"}. Fig. 3Inhibitory effect of *Ficus palmata* crude extract (Fp.Cr) and atropine on castor oil induced fluid accumulation in mice. Results are expressed as mean ± SEM, *n* = 5. Anti-secretory effect is expressed as Pi/Pm × 1000 (g) where Pi is the weight of the small intestine and Pm is the weight of mouse; ^\#^*p* \< 0.001 vs. saline group, ^\*\*\*^*p* \< 0.001 vs. castor oil group, one-way analysis of variance with *post-hoc* Tukey's test

Effect on spontaneous and K^+^ induced contractions {#Sec16}
---------------------------------------------------

Figure [6](#Fig6){ref-type="fig"} shows comparative inhibitory effect of the plant extract and verapamil against spontaneous and K^+^ (80 mM)-induced contractions. Fp.Cr was found to be equally effective against spontaneous and K^+^ (80 mM)-induced contractions with EC~50~ values of 0.11 mg/mL (0.08--0.1, *n* = 4) and 0.16 mg/mL (0.09--0.2, n = 4) respectively as shown in Fig. [4a](#Fig4){ref-type="fig"}. With EC~50~ value of 0.04 μM (0.03--0.06, n = 4), verapamil was found more potent against K^+^ (80 mM)-induced contractions, as compared to spontaneous contractions \[0.12 μM (0.10--0.20, *n* = 3)\] as shown in Fig. [4b](#Fig4){ref-type="fig"}. Fig. 4Dose-dependent inhibitory effect on spontaneous and K^+^ (80 mM) induced contractions of (**a**) *Ficus palmata* crude extract (Fp.Cr) and (**b**) verapamil in isolated tissue preparations. Result expressed as mean ± SEM, *n* = 3--5

Effect on ethanol-HCl induced ulcer {#Sec17}
-----------------------------------

Fp.Cr in dose dependent manner (50--300 mg/kg) exhibited an anti-ulcer effect. Fp.Cr at 50, 100 and 300 mg/kg caused 21.1, 42.2 and 73.3% (*p* \< 0.001 vs. saline group) inhibition respectively. Omeprazole (20 mg/kg) showed 88.8% protective effect (Table [2](#Tab2){ref-type="table"}). Macroscopic observation showed the gastric mucosa of rats (Fig. [5](#Fig5){ref-type="fig"}). Table 2Protective effect of *Ficus palmata crude extract* (Fp.Cr) and omeprazole against ethanol-HCl induced gastric ulcers in ratsTreatmentUlcer Index% InhibitionSaline 10 mL/kg + Ethanol-HCl9.0 ± 0.07--Fp.Cr (50 mg/kg) + Ethanol-HCl7.1 ± 0.20^\*\*\*^21.1Fp.Cr (100 mg/kg) + Ethanol-HCl5.2 ± 0.14^\*\*\*^42.2Fp.Cr (300 mg/kg) + Ethanol-HCl2.4 ± 0.14^\*\*\*^73.3Omeprazole (20 mg/kg) + Ethanol-HCl1 ± 0.11^\*\*\*^88.8^\*\*\*^*p* \< 0.001 compared to control saline group, one-way analysis of variance, followed by *Post-hoc* Tukey's test, *n* = 5 Fig. 5Gross-appearance of gastric mucosa in rat: (**a**) pre-treated with saline, 10 mL/kg (ulcer control). Severe injuries are seen, as ethanol-HCl (1 mL/100 g) produced excessive hemorrhagic necrosis of gastric-mucosa (**b**, **c** & **d**) pretreated with *Ficus palmata* crude extract (Fp.Cr) at doses of 50, 100, 300 mg/kg and (**e**) pretreated with omeprazole 20 mg/kg. The injuries reduce with increase of Fp.Cr doses and omeprazole compare with ulcer-control. At 300 mg/kg, Fp.Cr showed most efficacious gastro protective action

Effect on charcoal meal transit time {#Sec18}
------------------------------------

Fp.Cr hinders the charcoal meal to travel through the small intestine in a dose dependent manner. The distance travelled by the saline group was 82.29%. Fp.Cr at 50, 100 and 300 mg/kg dose shows inhibition of charcoal meal transit by 50.84, 48.46 and 45.87% respectively (*p* \< 0.001 vs. saline group). Atropine (0.1 mg/kg, i.p.) shows inhibitory effect of 44.23% (Table [3](#Tab3){ref-type="table"}). Table 3Effect of *Ficus palmata* crude extract (Fp.Cr) and atropine on charcoal meal transit time in ratsTreatment (mg/kg)Mean length of Intestine (cm)Distance Moved by Charcoal (cm)Intestinal transit %Saline (10 mL/kg)86.00 ± 0.370.32 ± 0.682.29Fp.Cr (50 mg/kg)88.66 ± 0.545.08 ± 0.4^\*\*\*^50.84Fp.Cr (100 mg/kg)86.66 ± 0.442.00 ± 0.3^\*\*\*^48.46Fp.Cr (300 mg/kg)87.00 ± 0.440.00 ± 0.5^\*\*\*^45.87Atropine (0.1 mg/kg, i.p.)90.8 ± 0.638.32 ± 0.4^\*\*\*^44.23^\*\*\*^*p* \< 0.001 compared to control saline group, one-way analysis of variance followed by *Post-hoc* Tukey's test, n = 5

Docking evaluation {#Sec19}
------------------

Assessment of E-value is an important contributor which helps in docking evaluation. Table [4](#Tab4){ref-type="table"} shows the values of atomic energy in Kcal/mol for complexes formed between ligand and target receptor. Binding residues involved in the formation of polar hydrogen bonds and total number of hydrogen bonds is expressed in Table [5](#Tab5){ref-type="table"}. Total number of pi-pi bonds and binding residues forming these bonds are represented in Table [6](#Tab6){ref-type="table"}. Other hydrophobic bonding of best models for ligand-target complexes are represented in Table [7](#Tab7){ref-type="table"}. Formation of bonding and interaction by bergapten, psoralene, psoralenoside, germanicol acetate and standard drugs against adrenergic α~1~ receptor, muscarinic M~1~, muscarinic M~3~, dopaminergic D~2~, calmodulin, mu-opioid, voltage gated L-Type calcium channel, histaminergic H~1~, histaminergic H~2~ and H^+^/K^+^ ATPase pump are shown in Figs. [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}, [8](#Fig8){ref-type="fig"}, [9](#Fig9){ref-type="fig"}, [10](#Fig10){ref-type="fig"}, [11](#Fig11){ref-type="fig"}, [12](#Fig12){ref-type="fig"}, [13](#Fig13){ref-type="fig"}, [14](#Fig14){ref-type="fig"} and [15](#Fig15){ref-type="fig"} respectively. Table 4E-values (Kcal/mol) of best docked poses of bergapten, psoralene, psoralenoside, germanicol acetate and standard drugs against targets: adrenergic α~1~ receptor, muscranic M~1~, muscranic M~3~, dopaminergic D~2~, calmodulin, mu-opioid, voltage gated L-Type calcium channel, histaminergic H~1~, histamergic H~2~ and H^+^/K^+^ ATPase pumpTarget ProteinsPDB IDBargaptenPsoralenePsoralenosideGermanicol acetateStandard drugsAdrenergic α~1~3538−7.7−8.1−7.010.3−8.0^A^Muscranic M~1~5CXV−8.1−8.2−7.8− 10.5− 9.0^B^Muscranic M~3~4 U14−7.5−7.6− 7.9− 9.7− 8.6^C^Dopaminergic D~2~6CM4− 7.4− 8.7−7.39.7−10.6^D^Calmodulin1CTR−5.8− 5.8− 6.0− 9.2− 8.3^E^Calcium channel1T3S−6.2− 6.2− 6.5− 9.2− 7.9^F^Histaminergic H~1~3RZE− 6.6−6.5−7.0− 9.0−5.7^G^H^+^/K^+^ ATPase5YLU−7.4−8.7−8.6− 9.6− 8.4^H^Histaminergic H~2~P25021−8.2−8.2− 8.0− 9.2−6.1^I^Mu Opioid5C1M−7.3− 7.4− 7.7− 9.3− 9.2^**J**^Standard inhibitors or activator of pathways are: (A) piranzapine, (B) phenoxy benzamine (C) atropine, (D) domperidone, (E) calmozolium, (F) verapamil, (G) pyrilimine, (H) omeprazole, (I) ranitidine and (J) loperamide Table 5Hydrogen bonds (H-bonds) formed by bergapten, psoralene, psoralenoside, germanicol acetate and standard drugs against targets: adrenergic α~1~ receptor, muscranic M~1~, muscranic M~3~, dopaminergic D~2~, calmodulin, mu-opioid, voltage gated L-Type calcium channel, histaminergic H~1~, histamergic H~2~ and H^+^/K^+^ ATPase pumpTarget ProteinsPDB IDBargaptenPsoralenePsoralenosideGermanicol acetateStandard drugsH-bondsAmino AcidsH-bondsAmino AcidsH-bondsAmino AcidsH-bondsAmino AcidsH-bondsAmino AcidsAdrenergic α~1~35380--4SER 180(2)THR 181THR 1025THR 78THR 323ASP 320GLN 9GLY 811THR 2830^A^--Muscranic M~1~5CXV2CYS 407SER 1091ASN 3820--0--2^B^ILE 180TYR 381Muscranic M~3~4 U141SER 1510--2GLU 1011ASP 10101TYR 1480^C^--Dopaminergic D~2~6CM41TYR 4161SER 1931SER 4091ILE 4032^D^TYR 413GLU 95Calmodulin1CTR0--0--3GLU 114GLU 14GLU 1270--0^E^--Calcium channel1T3S1ARG 1681ARG 1683SER 177ASN 123ASP 1262GLY 178SER 1772^F^GLN 1156ILE 381Histaminergic H~1~3RZE1TRP931TRP 934SER 128ARG 125ASN 63ASN 4720--**0**^G^--H^+^/K^+^ ATPase5YLU2THR 799TYR 3081ARG 5445ALA 730ASP 710ASP 369SER 477ASN 7130--1^H^SER 477Histaminergic H~2~P250213SER 185SER 181THR 1733SER 185SER 181THR 1734TYR 275CYS 169ASP 170THR 1730--2^I^THR 173Mu Opioid5C1M1HIS 2971ASN 3823TYR 1018ASN 1020GLU 10110--1^J^TYR 128Standard inhibitors or activators are: (A) piranzapine, (B) phenoxy benzamine, (C) atropine, (D) domperidone, (E) calmozolium, (F) verapamil (G) omeprazole, (I) ranitidine, and (J) loperamide. Amino acids are: ALA, alanine; ARG, arginine; ASN, asparagine; ASP, aspartic acid; CYS, cysteine; GLN, glutamine; GLU, glutamic acid; GLY, glycine; HIS, histidine; ILE, isoleucine; LYS, lysine; MET, methionine; PHE, phenylalanine; PRO, proline; SER, serine; THR, threonine; TRP, tryptophan; TYR, tyrosine and VAL, valine Table 6Pi-Pi bonds (p-p bonds) formed by Bargapten, Psoralene, Psoralenoside, Germanicol acetate and standard drugs against targets: adrenergic α~1~ receptor, muscranic M~1~, muscranic M~3~, dopaminergic D~2~, calmodulin, mu-opioid, voltage gated L-Type calcium channel, histaminergic H~1~, histaminergic H~2~ and H^+^/K^+^ ATPase pumpProteinsPDB IDBargaptenPsoralenePsoralenosideGermanicol acetateStandard drugsπ-π bondsAmino Acidsπ-π bondsAmino Acidsπ-π bondsAmino Acidsπ-π bondsAmino Acidsπ-π bondsAmino AcidsAdrenergic α~1~35382TRP 295PHE 2991PHE 299CYS 1811VAL 1680--3^A^PHE 299TRP 295PHE 298Muscranic M~1~5CXV2TYR 381TYR 1063TYR 404TRP 378CYS 4072ALA 363LYS 3620--1^B^TYR 404Muscranic M~3~4 U141TYR 5061TRP 5031TYR 10180--0^C^--Dopaminergic D~2~6CM44TRP 386PHE 386PHE 390ASP 1144PHE 390TRP 386PHE 198PHE 3892THR 412TRP 1001TYR 4084^D^ASP 114PHE 389LEU 94TRP 100Calmodulin1CTR2MET 124PHE 921LEU 1052GLU 11MET 720--5^E^MET 144MET 145MET 109LEU 105PHE 92Calcium channel1T3S3LEU 86GLU 872ARG 65GLU 870--0--1^F^ARG 413Histaminergic H~1~3RZE2ARG 97CYS 1802ARG 97CYS 1800--0--2^G^PHE 1104GLU 1011H^+^/K^+^ ATPase5YLU1PHE 9091GLY 6111ASP 4430--1^H^ARG 544Histaminergic H~2~P250212PHE 249PHE 1713PHE 171PHE 249VAL 921PHE 1710--2^I^PHE 267VAL 268Mu Opioid5C1M3VAL 300MET 151TRP 2933TYR 494CYS 407TRP 3782THR 1142ARG 11451PHE 2393^J^ILE 296HIS 297TRP 293Standard inhibitors or activators are: (A) phenoxy benzamine, (B) piranzapine, (C) atropine, (D) domperidone, (E) calmozolium, (F) verapamil, (G) pyrilimine, (H) omeprazole, (I) ranitidine and (J) loperamide. Amino acids are: ALA, alanine; GLN, glutamine; GLY, glycine; HIS, histidine; LYS, lysine; PHE, phenylalanine; SER, Serine; TRP, tryptophan and TYR, tyrosine and VAL, valine Table 7Hydrophobic interactions formed by bergapten, psoralene, psorelenoside, germanicol acetate and standard drugs against targets: adrenergic α~1~ receptor, muscranic M~1~, muscranic M~3~, dopaminergic D~2~, calmodulin, mu-opioid, voltage gated L-Type calcium channel, histaminergic H~1~, histamergic H~2~ and H^+^/K^+^ ATPase pumpTarget proteinsPDB IDBargaptenPsoralenePsoralenosideGermanicol acetateStandard drugsAdrenergicα~1~3538ALA 184CYS 101ILE 98VAL 169VAL 169ALA 184ILE 98MET 305ARG 276VAL 245,242MET 273ALA 280,274ALA 184LE 98CYS 101VAL 169VAL 168^**[A]{.ul}**^Muscranic M~1~5CXV--ALA 196--ILE 119LEU 64,367ALA 363ARG 123LEU 183TYR 106^**[B]{.ul}**^Muscranic M~3~4 U14ALA 238, CYS 532CYS 532ALA 238ARG 1014ILE 128,222TYR 127,506ASN 526,131TRP 525TYR 533, 529CYS 532TRP 503VAL 155ALA 238^**[C]{.ul}**^Dopaminergic D~2~6CM4CYS 118HIS 393VAL 115CYS 118ALA 122VAL 91TYR 408TYR 416LEU 94ILE 184TRP 100PHE 202ILE 383TYR 213ALA 376GLN 373^**[D]{.ul}**^Calmodulin1CTRLEU 105MET 144ILE 100ALA 128VAL 136ILE 100ILE 125VAL 136ALA 15ILE 119LEU 347,64ALA 363VAL 127PHE 19LEU 116LEU 18ALA 15VAL 136ALA 100^**[E]{.ul}**^Calcium channel1T3S----LYS 51THR 55GLU 49VAL 48LEU 24,58TYR 108LYS 1170THR 1471ASP 1468TYR 1163^**[F]{.ul}**^Histaminergic H~1~3RZEASP 91VAL 95VAL 92ASN 252ASN 252VAL 95ASP 91ASN 252GLY 239TYR 201MET 238LEU 198,231ALA 197,204ALA 1074ALA 1073LEU 1032^**[G]{.ul}**^H^+^/K^+^ ATPase5YLUVAL 798ARG 972GLY 796LYS 501LYS 480ALA 503GLY 611GLY 711VAL 712LYS 187THR 371LYS 719VAL 243PRO 716, 688GLY 245PHE 475VAL 712ASN 713LYS 187^**[H]{.ul}**^Histaminergic H~2~P25021ASP 91VAL 95VAL 92ASN 252VAL 95GLY 239MET 238LEU 198, 231HIS 228ALA 197ALA 269VAL 72, 268TRP 265TYR 275ASN 271ALA 178^**[I]{.ul}**^Mu-Opioid5C1MILE 296VAL 236SER 109ALA 196ILE 198PHE 156LEU 196ALA 197ILE 322, 296TRP 318VAL 300HIS 319TYR 128ILE 296TYR 326VAL 300MET 151ILE 322^**[J]{.ul}**^Standard inhibitors or activators are: (A) phenoxy benzamine, (B) piranzapine, (C) atropine, (D) domperidone, (E) calmozolium, (F) verapamil, (G) pyrilimine, (H) omeprazole, (I) ranitidine, and (J) loperamid.. Amino acids are: ALA, alanine; ARG, arginine; ASN, asparagine; ASP, aspartic acid; CYS, cysteine; GLN, glutamine; GLU, glutamic acid; GLY, glycine; HIS, histidine; ILE, isoleucine; LYS, lysine; MET, methionine; PHE, phenylalanine; PRO, proline; SER, serine; THR, threonine; TRP, tryptophan; TYR, tyrosine and VAL, valine Fig. 6**a**, **b**, **c**, **d** and (**e**) represents interactions of bergapten, psoralene, psoralenoside, germanicol acetate and phenoxy benzamine against target: adrenergic α~1~ receptor respectively, evaluated through Biovia Discovery Studio 2016 Fig. 7**a**, **b**, **c**, **d** and (**e**) represents interactions of bergapten, psoralene, psoralenoside, germanicol acetate and piranzapine against target: muscranic M~1~ receptor respectively, evaluated through Biovia Discovery Studio 2016 Fig. 8**a**, **b**, **c**, **d** and (**e**) represents interactions of bergapten, psoralene, psoralenoside, germanicol acetate and atropine against target: musranic M~3~ receptor respectively, evaluated through Biovia Discovery Studio 2016 Fig. 9**a**, **b**, **c**, **d** and (**e**) represents interactions of bergapten, psoralene, psoralenoside, germanicol acetate and domperidone against target: dopaminergic D~2~ receptor respectively, evaluated through Biovia Discovery Studio 2016 Fig. 10**a**, **b**, **c**, **d** and (**e**) represents interactions bergapten, psoralene, psoralenoside, germanicol acetate and calmozolium against target: calmodulin receptor respectively, evaluated through Biovia Discovery Studio 2016 Fig. 11**a**, **b**, **c**, **d** and (**e**) represents interactions of bergapten, psoralene, psoralenoside, germanicol acetate and verapamil against target: voltage gated L-Type calcium channels respectively, evaluated through Biovia Discovery Studio 2016 Fig. 12**a**, **b**, **c**, **d** and (**e**) represents interactions of bergapten, psoralene, psoralenoside, germanicol acetate and pyrilimine against target: histaminergic H~1~ receptor respectively, evaluated through Biovia Discovery Studio 2016 Fig. 13**a**, **b**, **c**, **d** and (**e**) represents interactions of bergapten, psoralene, psoralenoside, germanicol acetate and omeprazole against target: H^+^/K^+^ ATPase receptor respectively, evaluated through Biovia Discovery Studio 2016 Fig. 14**a**, **b**, **c**, **d** and (**e**) represents interactions of bergapten, psoralene, psoralenoside, germanicol acetate and ranitidine against target: histaminergic H~2~ receptor respectively, evaluated through Biovia Discovery Studio 2016 Fig. 15**a**, **b**, **c**, **d** and **e** represents interactions bergapten, psoralene, psoralenoside, germanicol acetate and loperamide against target: mu-opioid receptor respectively, evaluated through Biovia Discovery Studio 2016

Discussion {#Sec20}
==========

Based on ethnopharmacological use of *Ficus palmata* in hyperactive gut diseases, such as colic and diarrhea, its extract was evaluated for the possible anti-diarrheal, anti-secretory, charcoal meal gastrointestinal motility and anti-ulcer effects in rodents. Isolated intestinal tissue was used for the elucidation of possible underlying mechanism(s) to rationalize aforementioned ethnomedicinal uses of the plant and it was further supported by virtual screening tool**s.**

Fp.Cr demonstrated an excellent antidiarrheal activity against castor oil induced diarrhea similar to the effect produced by loperamide, a standard drug \[[@CR13]\]. Castor oil cause increases in the peristaltic activity and induce permeability changes to electrolytes and water in the mucosal membrane of the small intestine similar to an effect which is associated with prostaglandin release. Ricinoleic acid which is an active metabolite of castor oil is another major factor in causing diarrhea through a series of actions including activation of small intestinal peristaltic activity with reduction of Na^+^/K^+^ ATPase activity. These changes eventually results in disturbance in the intestinal mucosa, electrolyte permeability, hypersecretion of intestinal contents and a slogging of the transport time in the intestine \[[@CR19]\]. Thus, a potential agent may exhibit its anti-diarrheal activity by these mechanisms. Intracellular Ca^2+^ levels had a huge impact on secretary functions of the gastrointestinal organs which lead towards consequences such as discharge of gastric acids and intestinal fluid release. This effect might be affected by some drugs that hinder calcium influx \[[@CR20]\]. Fp.Cr shows protection against castor oil induced intestinal fluid secretions in mice. The anti-diarrheal and anti-secretory activities of Fp.Cr might be because of gastrointestinal relaxant component(s) present in the Fp.Cr \[[@CR10]\].

Dose-dependent inhibition of spontaneous contractions in isolated rabbit jejunum preparations were exhibited by Fp.Cr, thus showing antispasmodic action. High K^+^ (80 Mm), as KCl, was used to depolarize the tissue to analyze whether the spasmolytic activity of this extract was mediated through calcium channel blockade or some other mechanism. High K^+^ (80 Mm) is known to cause smooth muscle contractions with opening of voltage gated L-type calcium channels, thus permitting the inflow of extracellular calcium causing contractility and the substance causing this inhibition of high K^+^-induced contractions is considered as calcium channel blocker \[[@CR15]\]. Verapamil, a specific calcium antagonist have inhibitory effect against K^+^-induced contractions. Against spontaneous and K^+^-induced contractions Fp.Cr produces inhibitory pattern just like verapamil.

Gastric ulcer is the result of an imbalance between aggressive and defensive factors of the gastric mucosa which results in rupturing of mucosal protection and expose gastric lining to gastric acids. To explore the anti-ulcer effect of Fp.Cr, ethanol-HCl induced gastric model was used which through variety of mechanisms stimulates ulcer including mucus exhaustion, mucosal damage, release of superoxide anion, hydro-peroxy free radicals, all these mechanisms prolonged the tissue oxidative stress and release of inflammatory mediators. Fp.Cr significantly decreased the surface ulceration as compared to that of control animals which received saline. In view of these results, methanol extract showed significant cytoprotection. The potential of Fp.Cr to produce anti-ulcer effect might be due to its CCB effect, as Ca^2+^ antagonist are well known to demonstrate such effects \[[@CR21]\]. In pathophysiology of gastric ulcers, oxidative stresss plays a vital role. Antioxidant and nitric oxide free scaveneging activity has been reported by *Ficus palmata* \[[@CR10]\] which may be responsible for its effectiveness as anti-ulcer agent.

Intestinal transit travelling, an important measurement factor that regulates the bioavailability of orally administered drugs/foods and determines the absorption intensity of luminal contents. More oftenly, timely oral administration of active charcoal, as marker, to experimental animals are useful to measure the intestinal transit rate. This experimental model is sensitive to agents that inhibit/stimulate intestinal peristalsis regulated by autonomic nervous system. This is the rationale for using this assay to investigate the influence of natural products on intestinal peristalsis \[[@CR22]\]. In the small intestinal transit test, Fp.Cr produces suppression of the propulsion of charcoal marker at all test doses just like atropine sulphate a standard drug, that has been reported to have anticholinergic effect on intestinal transit \[[@CR21]\]. A decrease in the motility of gut muscles increases the stay of substances in the intestine, thus allows better water absorption. This finding suggests that Fp.Cr has the ability to influence the peristaltic movement of intestine thereby indicating the presence of an anti-motility activity. It is therefore presumed that the reduction in the intestinal propulsive movement in the charcoal meal model may be due to antispasmodic properties of the Fp.Cr \[[@CR22]\].

The observed therapeutic effects of *Ficus palmata* may be due to the presence of phytochemicals, tannins and flavonoids, as these phytocontinuents are well known for gastrointestinal effects. Anti-diarrheal, anti-secretory, anti-ulcer and anti-spasmodic activities may be due to flavonoids \[[@CR23]\].

Molecular docking is an effective tool for evaluating the affinity of various protein targets that may possibly be associated with the pathophysiology of gastric disorders. The traditionally acclaimed use of *Ficus palmata* in the management of gastric related diseases has been supported with scientific evidence using virtual screening tool and different chemically-induced gastrointestinal models like castor oil induced diarrhea, castor oil induced enteropooling, and charcoal meal gastrointestinal motility. The use of computational methodologies has end up being fundamental component of drug discovery and development process therefore computational screening becomes broadly employed tool in identifying the potential of structural chemical compounds before initiation of wet lab research. Since early 90's, docking has been observed to play a primary role for virtual screening of different chemical structures and it is still an extremely dynamic region to look forward \[[@CR24]\]. Lead compounds are virtually screened through molecular docking that turns out to be time saving as well as economically affordable on premise of structural conformations \[[@CR25]\].

In this study, Auto Dock Vina program was used through PyRx \[[@CR26]\]. Through gradient optimization method, binding mode predictions are improved. E-value, Lower desolvation, Hydrogen bonding, pi--pi and other hydrophobic interactions imparts their influential effect in gastrointestinal diseases \[[@CR27]\] which are contributing factors in increasing affinity with protein and stabilization of ligand-receptor complex. It has been found that psoralenoside showed excellent score of binding against α~1~ receptor with lowest E-value. This binding efficacy is greater than majority of the target proteins with better affinity as compared to other test compounds and standard drugs. Order of affinity of test compounds for α~1~ and M~1~ receptor was; psoralenoside \> bergapten \> psoralene \> germanicol acetate. Compounds with higher affinity all together formed stronger pi--pi bonds, high number of hydrophobic interactions and polar hydrogen bonding against muscarinic M~1~ and α~1~ receptors. The order of affinity for ligands against muscranic M~3~ receptor was found as; bergapten \> psoralene \> psoralenoside \> germanicol acetate. Order of affinity of test compounds for dopaminergic D~2~ receptor was found as; psoralenoside \> bergapten \> psoralene \> germanicol acetate. Alongside hydrogen and hydrophobic interactions, different types of interactions, for example alky, pi-alky and vander waal interactions are appeared with high proclivity by test compounds. The affinity order of ligands against calmodulin was found as; bergapten \> psoralene \> psoralenoside \> germanicol acetate. In addition, hydrogen bond is considered to be vital for complex of ligand with calmodulin. The affinity order for test compounds for voltage gated L-Type calcium channel was found as; bergapten \> psoralene \> psoralenoside \> germanicol acetate. Order of affinity of test compounds for histaminergic H~1~ receptor was found to be: psoralene \> bergapten \> psoralenoside \> germanicol acetate. Ligands are not engaged with making any solid interactions on stated restricting sites. Order of affinity of test compounds for H^+^/K^+^ ATPase receptor was found as; bergapten \> psoralenoside \> psoralene \> germanicol acetate. Hydrogen and hydrophobic associations are observed to be essential but no such interactions of test compounds with stated restricting site were seen \[[@CR28]\]. In this regard, SER 477 is considered as important and vital amino acid. The affinity order of ligands against histaminergic H~2~ receptor was found as; psoralenoside \> psoralene \> bergapten \> germanicol acetate. Order of affinity of test compounds for mu-opioid receptor was found as: bergapten \> psoralene \> psoralenoside \> germanicol acetate. Ligands having high restricting proclivity shaped interacts with TYR 272 and VAL 270.

Conclusions {#Sec21}
===========

*Ficus palmata* exhibited anti-diarrheal, anti-secretary, anti-spasmodic, anti-motility and anti-ulcer effects. The plant constituents: psoralenoside and bergapten showed high binding affinities (E-value ≥ − 6.5 Kcal/mol) against histaminergic H~1~, calmodulin and voltage gated L-type calcium channels, while showed moderate affinities (E-value ≥7 Kcal/mol) against dopaminergic D~2~, adrenergic α~1,~ muscarinic M~3~, mu-opioid, whereas revealed lower affinities (E-value ≥9.5 Kcal/mol) vs. muscarinic M~1~, histaminergic H~2~ and H^+^/K^+^ ATPase pump. Germanicol acetate and psoralene exhibited weak affinities against aforementioned targets.
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